Ebola Antibody Treatment Expands Availability

Maryland-based Emergent BioSolutions Inc. announced yesterday that it has agreed to expand the availability of Ebanga™, a monoclonal antibody (mAbs) with antiviral activity provided through a single injection.

Under the terms of the contemplated collaboration, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga in the USA and Canada.

And Miami-based Ridgeback Bio will serve as the global access partner for Ebanga.

Furthermore, Ridgeback is ensuring the mAbs remain available to patients in endemic countries free of charge through Ridgeback Bio's compassionate use program.

In 2020, Ridgeback initiated a compassionate use protocol for Ebola patients during an Ebola outbreak in the Équateur Province of the Democratic Republic of the Congo (DRC).

Ebanga was provided to all PCR-positive Ebola patients under this protocol.

"We're thrilled to collaborate with Emergent BioSolutions in making sure that the United States and Canada receive the supply they need of Ebanga while also continuing our ongoing local support for the prompt treatment of outbreaks that includes free patient access and funding on-the-ground support through our Rapid Response Program," said Wendy Holman, CEO of Ridgeback Bio, in a related press release issued on July 7, 2022.

Ebanga was approved by the U.S. FDA in December 2020 for the treatment of the Zaire Ebolavirus but has been limited in distribution.

The WHO African Region recently confirmed the 14th Zaire Ebolavirus outbreak in the DRC ended on July 4, 2022.

Ebola vaccine information is posted on this Vax-Before-Travel webpage.

Note: This news was manually curated for mobile travelers.